Amgen, Inc. vs Bill.com Holdings Inc — how do they compare? Amgen, Inc. trades at $414.3 (market cap $224.14B), while Bill.com Holdings Inc trades at $49.01 (market cap $4.93B). The key difference: Amgen, Inc. is far larger — about 45.5× Bill.com Holdings Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | BILL | |
|---|---|---|
Market Cap | $224.14B | $4.93B |
Sector | Health | Technology |
52-Week High | $417.20 | $56.32 |
52-Week Low | $271.18 | $31.96 |
Enterprise Value | $267.45B | $4.64B |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →